These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33782477)

  • 1. A novel scoring system for TIGIT expression in classic Hodgkin lymphoma.
    Annibali O; Bianchi A; Grifoni A; Tomarchio V; Tafuri M; Verri M; Avvisati G; Crescenzi A
    Sci Rep; 2021 Mar; 11(1):7059. PubMed ID: 33782477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma.
    Solórzano JL; Menéndez V; Parra E; Solis L; Salazar R; García-Cosío M; Climent F; Fernández S; Díaz E; Francisco-Cruz A; Khoury J; Jiang M; Tamegnon A; Montalbán C; Melero I; Wistuba I; De Andrea C; F García J
    Oncoimmunology; 2024; 13(1):2388304. PubMed ID: 39135889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
    Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.
    Gunawardana J; Law SC; Sabdia MB; Fennell É; Hennessy A; Leahy CI; Murray PG; Bednarska K; Brosda S; Trotman J; Berkahn L; Zaharia A; Birch S; Burgess M; Talaulikar D; Lee JN; Jude E; Hawkes EA; Jain S; Nath K; Snell C; Swain F; Tobin JWD; Keane C; Shanavas M; Blyth E; Steidl C; Savage K; Farinha P; Boyle M; Meissner B; Green MR; Vega F; Gandhi MK
    Am J Hematol; 2024 Nov; 99(11):2096-2107. PubMed ID: 39152767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
    Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
    Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
    Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
    Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells.
    Satou A; Takahara T; Yamashita D; Seki M; Kato S; Tanioka F; Tsuyuki T; Wada E; Sakurai K; Karube K; Tsuzuki T; Nakamura S
    Am J Surg Pathol; 2023 Aug; 47(8):897-906. PubMed ID: 37248961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.
    Li W; Blessin NC; Simon R; Kluth M; Fischer K; Hube-Magg C; Makrypidi-Fraune G; Wellge B; Mandelkow T; Debatin NF; Pott L; Höflmayer D; Lennartz M; Sauter G; Izbicki JR; Minner S; Büscheck F; Uhlig R; Dum D; Krech T; Luebke AM; Wittmer C; Jacobsen F; Burandt E; Steurer S; Wilczak W; Hinsch A
    BMC Cancer; 2018 Dec; 18(1):1209. PubMed ID: 30514251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass cytometry of Hodgkin lymphoma reveals a CD4
    Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
    Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings.
    Gupta GK; Agrawal T; Pilichowska M
    BMC Cancer; 2020 Jun; 20(1):535. PubMed ID: 32513132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint inhibition enhances cell contacts between CD4
    Yadigaroglu K; Scharf S; Gretser S; Schäfer H; Deli ASS; Loth AG; Yegoryan H; Schmitz R; Donnadieu E; Hansmann ML; Hartmann S
    Haematologica; 2024 Oct; 109(10):3295-3304. PubMed ID: 38779721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital spatial profiling of CD4
    Takeuchi M; Miyoshi H; Semba Y; Yamada K; Nakashima K; Sato K; Furuta T; Moritsubo M; Ogura Y; Tanaka K; Imamoto T; Arakawa F; Kohno K; Ohshima K
    Virchows Arch; 2023 Aug; 483(2):255-260. PubMed ID: 37270432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
    Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
    In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
    Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
    Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.